



Financial Tear Sheet

Corporate Profile

Rigel's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

Date	Title
12/08/17	Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
11/07/17	Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update

Stock Performance

RIGL (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.68
Change (%)	-0.3 (7.54%)
Volume	1,885,769
Data as of 12/11/17 4:00 p.m. ET Refresh quote	



Data provided by Nasdaq. Minimum 15 minutes delayed.

SEC Filings

Filing Date	Form
11/07/17	4
11/07/17	S-8

Primary IR Contact

Ryan Maynard
 CFO
 Phone: (650) 624-1284
 E-mail: invrel@rigel.com